Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

575.50GBp
9 Dec 2016
Change (% chg)

18.50p (+3.32%)
Prev Close
557.00p
Open
560.50p
Day's High
577.50p
Day's Low
558.50p
Volume
627,281
Avg. Vol
580,850
52-wk High
739.50p
52-wk Low
550.50p

BTG.L

Chart for BTG.L

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.17
Market Cap(Mil.): £2,216.19
Shares Outstanding(Mil.): 385.09
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 101.30 29.74 30.36
EPS (TTM): 0.06 -- --
ROI: 2.12 15.91 15.27
ROE: 2.55 17.01 16.60

BRIEF-BTG reports 24 pct rise in first half revenue to 285.4 mln stg

* Says business has performed well during first half, and outlook for full year is strong

15 Nov 2016

BTG unit pleads guilty in U.S. to misbranding, to pay $36 million

A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to improperly marketing its embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability, the U.S. Department of Justice said.

08 Nov 2016

UPDATE 1-BTG unit pleads guilty in U.S. to misbranding, to pay $36 mln

Nov 7 A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to improperly marketing its embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability, the U.S. Department of Justice said.

08 Nov 2016

BTG unit pleads guilty in U.S. to misbranding, to pay $36 mln

Nov 7 A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to a misdemeanor related to its misbranding of the embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability, the U.S. Department of Justice said.

08 Nov 2016

British healthcare firm BTG settles DoJ probe into U.S. unit

Oct 6 British healthcare group BTG Plc said it agreed to settle an investigation into one of its U.S. units, Biocompatibles, with the U.S. Department of Justice for $36 million.

06 Oct 2016

BRIEF-BTG's Biocompatibles to settle LC Bead probe for $36 mln

* Unit Biocompatibles subsidiary reached a settlement with U.S. government in relation to department of justice's investigation of marketing of LC Bead

06 Oct 2016

CORRECTED-BRIEF-BTG raises revenue guidance on boost from the weaker pound

* On basis of current foreign exchange rates, reported full year revenue is now anticipated to be ahead of our previously announced guidance range of £510m-£540m

06 Oct 2016

BRIEF-BTG trading in line, guides revenue to 510-£540 mln stg on FX

* Overall performance and trading since 1 april 2016 are in line with expectations

14 Jul 2016

Earnings vs. Estimates